Craneware stock analysis
Craneware (3X6) Stock Price & Analysis
3X6 Stock Chart & Stats
- Day’s Range
- EUR 11.80 - EUR 12.20
- 52-Week Range
- EUR 11.00 - EUR 24.80
- Previous Close
- EUR 12.30
- Volume
- N/A
- Average Volume (3M)
- 3
- Market Cap
- EUR 420.04M
- Enterprise Value
- EUR 462.47M
- Total Cash (Recent Filing)
- EUR 55.10M
- Total Debt (Recent Filing)
- EUR 46.77M
- Price to Earnings (P/E)
- 25.1
- Beta
- 0.91
- Next Earnings
- Mar 08, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.19%
Bulls Say, Bears Say
Bulls Say
Recurring Revenue And Retention
A substantial recurring revenue base with approximately 100% net revenue retention and customer retention above 90% supports visibility and reduces dependence on new bookings. These characteristics also create opportunities to expand module adoption within established hospital relationships over the next several quarters.
Cash Generation And Liquidity
Strong cash conversion and net cash after bank debt provide financial flexibility to fund product investment, absorb operating volatility, and support customers through disruption. Undrawn credit capacity further strengthens Craneware’s ability to pursue its strategy without relying solely on near-term operating cash flow.
Product Investment And Innovation
Continued investment in data integration, AI-enabled applications, and pharmacy capabilities can deepen the platform’s relevance to hospital finance and clinical workflows. Sustaining research and development at roughly 25%–30% of revenue supports product differentiation and future expansion potential.
Bears Say
340B Exposure And Revenue Reset
The fiscal 2027 revenue reset indicates that growth has been deferred while Craneware faces uncertainty in the 340B market. Restrictions on 340B pricing and changing business models may continue to pressure transactional revenue, making near-term growth less predictable despite stable ARR.
Cybersecurity Exposure And Costs
The incident creates an ongoing business risk because data exposure may require continuing customer support, remediation, and compliance work. Management has not yet quantified the financial impact, and the possibility that costs extend across future periods reduces confidence in near-term earnings visibility.
Margin Pressure And Volatility
Lower gross margin and the expectation that margins will remain below 30% through fiscal 2027 indicate reduced earnings conversion during the transition period. The mix shift toward technology-enabled services and ongoing cost actions may constrain profitability until the planned fiscal 2028 recovery.
Craneware News
3X6 FAQ
What was Craneware’s price range in the past 12 months?
What is Craneware’s market cap?
When is Craneware’s upcoming earnings report date?
How were Craneware’s earnings last quarter?
Is Craneware overvalued?
Does Craneware pay dividends?
What is Craneware’s EPS estimate?
How many shares outstanding does Craneware have?
What happened to Craneware’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Craneware?
What is the TipRanks Smart Score and how is it calculated?
Craneware Stock Smart Score
Company Description
Craneware
Craneware plc, with its associated entities, is dedicated to creating, distributing, and maintaining cutting-edge software applications tailored for the U.S. healthcare industry. Its extensive suite of products is designed to streamline and improve a wide array of operational functions for healthcare organizations. Among its flagship offerings is the Chargemaster Toolkit, an automated, cloud-hosted platform for charge master administration, crucial for enabling providers to achieve optimal and legitimate revenue reimbursement. Trisus Supply facilitates the identification and resolution of data inconsistencies between disparate systems. The Physician Revenue Toolkit, a Software-as-a-Service (SaaS) solution, empowers the oversight of physician group performance indicators, billing rates, procedural codes, relative value units, and fee schedules. Complementing these are Reference Plus, another SaaS tool for comprehensive chargemaster analytics, and Pharmacy ChargeLink, engineered to bolster charge capture, pricing strategies, and cost control within pharmacy operations. Furthermore, the company offers integration software that autonomously uploads chargemaster modifications to patient billing systems, thereby ensuring billing precision. The Trisus Pricing Analyzer, a SaaS application, streamlines the pricing model development process. Extending its capabilities, Craneware delivers tools for regulatory adherence and financial oversight: InSight Medical Necessity, a SaaS solution for validating the medical necessity required by U.S. payers and for creating advance beneficiary notices; Trisus Claims Informatics, a program that automates the review of claims and coding; and InSight Audit, a browser-based audit management application for healthcare entities to handle governmental and commercial examinations. Additionally, the firm presents Trisus Healthcare Intelligence, a platform for cost analysis and resource optimization; solutions for pricing transparency; and InSight Denials, which facilitates the analysis, tracking, trending, and reporting of denial data, further supported by appeals management services. Beyond its software offerings, Craneware provides comprehensive client success management, specialized consulting, and an array of professional services. The organization also oversees its own sales, marketing efforts, and continuous product and software innovation. Founded in 1999, Craneware plc has its corporate headquarters situated in Edinburgh, United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Keith Neilson
- Employees
- 765
- Website
- www.thecranewaregroup.com
- Address
- 1 Tanfield, Edinburgh, SC, EH3 5DA, GB
Craneware (3X6) Earnings & Revenues
3X6 Earnings Call
Earnings Call SentimentNeutral
The call had a mixed but cautiously constructive tone. Management emphasized strong ARR, customer retention, cash generation, liquidity, long-term customer relationships, continued product investment, and customer support following the cyber incident. However, these positives were offset by revenue growth falling below expectations, the fiscal 2027 revenue reset to approximately $185 million, 340B-related transactional revenue pressure, lower gross margin, cybersecurity-related data exposure and unknown costs, and continued regulatory uncertainty. Management expects a return to growth and 30% plus margins in fiscal 2028, but fiscal 2027 is positioned as a transition year.
View all DE:3X6 earnings summaries3X6 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |
